PRP for Osteoarthritis: A Regenerative Alternative to Traditional Treatments Osteoarthritis (OA) is a progressive, degenerative joint disease characterized by cartilage breakdown, chronic inflammation, and joint dysfunction
The effects of tirzepatide on body weight control have also been confirmed in non-diabetic individuals in the SURMOUNT-1 study, where treatment with tirzepatide 1015 mg was associated with an average weight loss of approximately 20% at 72 weeks, exceeding 25% in one third of the patients
All peptides introduced to the market by Synrhagen are completely safe and show no side effects
Standard Contraindications Apply All GLP-1 contraindications remain in effect: personal or family history of medullary thyroid carcinoma, MEN2 syndrome, history of pancreatitis, pregnancy, and known hypersensitivity
Measurable body composition changes, the kind visible in before and after comparisons, generally appear at eight to twelve weeks of consistent use
